Inflammatory Bowel Disease (IBD) Database (Ongoing): Eligible patients are children with Crohn’s or UC. Long-term outcome of IBD patients. Only requires consent to follow and access medical records.
Quality of Life Survey in Pediatric IBD Patients: Eligible patients must have Crohn’s or UC and be concurrently enrolled in the database study.

Pathologic Markers of Genetic Damage and Disease in IBD: Enrolling IBD patients and healthy controls. Study involves single visit to the PCRC for blood and buccal cell collection and interview. Patients will be given a $10 gift certificate for their participation.

Mesalamine for ulcerative proctitis: We are enrolling pediatric patients age 6-17 with proctitis for a study to test mesalamine suppositories (500mg once or twice daily). The study, sponsored by AXCAN Pharma, is a 6 week study long and includes a baseline visit flex sig, one out-patient follow-up visit and final visit flex sig (which is optional). Patients will be reimbursed $100. Patients will not be billed for any visits or tests performed as part of this study.
Colazal for ulcerative colitis: We will soon be enrolling pediatric patients age 5-17 with mild to moderate ulcerative colitis.

GERD Patients We are enrolling patients age 5-11 with GERD (symptomatic gastroesophageal reflux) to test the PPI esomeprazole (Nexium). The study, sponsored by AstraZeneca, is for 11 weeks that includes 6 outpatient visits. Patients will be reimbursed for time in gift certificates. Patients will not be billed for any visits or tests performed as part of this study.